Read up on essential news

We want to keep you informed, so below are few important news and reminders for you this month:

**Changes to our National Precertification List (NPL)**

The following new-to-market drugs require precertification

- **Abecma®** (idecabtagene vicleucel) – Precertification required effective June 1, 2021. This drug is part of the Chimeric Antigen Receptor T-Cell Therapy (CAR-T) drug category.
- **Amondys 45™** (casimersen) – Precertification required for both the drug and site of care, effective June 1, 2021. This drug is part of the Muscular Dystrophy drug category.
- **Nulibry™** (fosdenopterin) – Precertification required effective June 1, 2021.
- **Pepaxto®** (melphalan flufenamide) – Precertification required effective June 1, 2021.
- **Jemperli®** (dostarlimab-gxly) – Precertification required for both the drug and site of care, effective July 1, 2021. This drug is part of the PD1/PDL1 drug category.
- **Zynlonta™** (loncastuximab tesirine-lpyl) – Precertification required effective July 1, 2021.

**Submitting precertification requests**

Be sure to submit precertification requests at least two weeks in advance.

To save time, request precertification online. Doing so is fast, secure and simple. You can submit most requests online through our provider portal on Availity®. Or you can use the Electronic Medical Record (EMR) system portal.
Are you asking for precertification on a specialty drug for a commercial or Medicare member? Then submit your request through Novologix, also available on Availity.

**Not registered for Availity?**

**Click here** or call **1-800-AVAILITY (282-4548)**. For one-on-one guided support from us, call **1-866-752-7021**. Then ask to talk with the Availity team.)

Please use our “Search by CPT code” search function on our [Precertification Lists webpage](#) to determine if the code requires precertification.

You can learn more on precertification under the General Information section of the [NPL](#).

**Aetna’s annual transition to the new edition of MCG**

We use evidence-based clinical guidelines from nationally recognized authorities to make UM decisions. MCG is one of the resources we use to make clinical decisions. Every year Aetna coordinates with MCG to update to their new edition.

On June 26, 2021, Aetna has updated to the 25th Edition of MCG and will be utilizing this edition for designated new review requests going forward.

---

**Aetna is the brand name used for products and services provided by one or more of the Aetna group of companies, including Aetna Life Insurance Company and its affiliates (Aetna).**

Aetna ®, CVS Pharmacy®, CVS® HealthHUB™ and MinuteClinic, LLC (which either operates or provides certain management support services to MinuteClinic®-branded walk-in clinics) are part of the CVS Health® family of companies. Health information programs provide general health information and are not a substitute for diagnosis or treatment by a health care professional.

**Help/contact us:**

If you have any questions, please [contact us](#).

Want to stop receiving messages like these through email? [Unsubscribe](#) at any time.

We are located at 151 Farmington Avenue, Hartford, CT 06156.

[Privacy Statement](#) | [Terms of Use](#) | [Privacy Information](#)

©2021 Aetna Inc.
34.36.805.1-JUL (07/21)